-+ 0.00%
-+ 0.00%
-+ 0.00%

Capstone swings to operating income of USD 432,000 in Q2 FY26; net sales rise 67% to USD 21.48 million

PUBT·08/12/2026 11:43:48
Listen to the news
Capstone swings to operating income of USD 432,000 in Q2 FY26; net sales rise 67% to USD 21.48 million
  • Capstone Therapeutics posted Q2 net sales of USD 21.48 million, up 67% year over year.
  • Net loss widened to USD 1.38 million; operating income swung to USD 432,000 from an operating loss.
  • Gross profit climbed to USD 6 million; gross margin rose 3.5 percentage points to 27.9%.
  • Interest and other expense widened to USD 1.96 million; SG&A increased 63% to USD 5.51 million.
  • Management cited acquisition contributions, a USD 438,000 tariff refund, and higher-margin Carolina Stone mix as key drivers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-027150), on August 12, 2026, and is solely responsible for the information contained therein.